huahaipharm(600521)2025-01-21 09:10Financial Performance Forecast - The estimated net profit attributable to shareholders for 2024 is expected to be between 1,140 million and 1,240 million CNY, representing a year-on-year increase of approximately 30.953 million to 40.953 million CNY, or a growth rate of about 37.3% to 49.3%[3] - The estimated net profit attributable to shareholders after deducting non-recurring gains and losses for 2024 is expected to be between 1,150 million and 1,250 million CNY, with a year-on-year increase of approximately 26.148 million to 36.148 million CNY, corresponding to a growth rate of about 29.4% to 40.7%[3] - The net profit for the same period last year was 830.466 million CNY, and the net profit after deducting non-recurring gains and losses was 888.522 million CNY[6] Factors Contributing to Profit Growth - The company attributes the significant profit growth to expanded sales scale, improved sales team structure, and effective market penetration strategies, along with the introduction of new products[7] - Continuous optimization of lean management and enhanced technical capabilities have contributed to improved cost control and increased gross margin, further strengthening the company's profitability[7] Performance Forecast Reliability - There are no major uncertainties affecting the accuracy of this performance forecast[8] - The performance forecast data is preliminary and has not been audited by an accounting firm; the final figures will be disclosed in the official 2024 annual report[9]